Financhill
Sell
37

BUDZ Quote, Financials, Valuation and Earnings

Last price:
$0.03
Seasonality move :
3.14%
Day range:
$0.03 - $0.03
52-week range:
$0.03 - $0.08
Dividend yield:
0%
P/E ratio:
180.00x
P/S ratio:
--
P/B ratio:
887.06x
Volume:
45.3K
Avg. volume:
27.9K
1-year change:
-55.6%
Market cap:
$4.2M
Revenue:
--
EPS (TTM):
-$0.01

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BUDZ
Weed
-- -- -- -- --
CAH
Cardinal Health
$55.3B $2.15 1.61% 104.13% $156.74
COR
Cencora
$75.8B $4.10 8.14% 56.12% $317.23
LAB
Standard BioTools
$40.1M -$0.04 7.07% -66.67% $2.38
MCK
McKesson
$94.2B $9.83 20.2% 18.43% $748.84
PNPL
Pineapple
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BUDZ
Weed
$0.03 -- $4.2M 180.00x $0.00 0% --
CAH
Cardinal Health
$154.44 $156.74 $36.9B 24.09x $0.51 1.31% 0.17x
COR
Cencora
$291.24 $317.23 $56.4B 33.79x $0.55 0.74% 0.19x
LAB
Standard BioTools
$1.01 $2.38 $364.9M -- $0.00 0% 2.23x
MCK
McKesson
$719.51 $748.84 $89.9B 27.86x $0.71 0.38% 0.26x
PNPL
Pineapple
$0.1000 -- $7.3M -- $0.00 0% 49.15x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BUDZ
Weed
-- -1.086 -- --
CAH
Cardinal Health
162.31% 0.200 22.64% 0.44x
COR
Cencora
88.58% 0.081 14.53% 0.48x
LAB
Standard BioTools
0.07% -0.535 0.07% 5.22x
MCK
McKesson
157.93% 0.870 6.69% 0.51x
PNPL
Pineapple
-- 2.419 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BUDZ
Weed
-- -$434.7K -- -- -- -$71.8K
CAH
Cardinal Health
$2.1B $656M 46.27% -- 1.35% $2.8B
COR
Cencora
$3.1B $1.2B 24.2% 183.42% 1.41% $3.2B
LAB
Standard BioTools
$19.7M -$30.3M -24.87% -26.52% -64.18% -$35.3M
MCK
McKesson
$3.6B $1.7B 79.77% -- 1.72% $7.5B
PNPL
Pineapple
-- -- -- -- -- --

Weed vs. Competitors

  • Which has Higher Returns BUDZ or CAH?

    Cardinal Health has a net margin of -- compared to Weed's net margin of 0.92%. Weed's return on equity of -- beat Cardinal Health's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BUDZ
    Weed
    -- -$0.00 --
    CAH
    Cardinal Health
    3.87% $2.10 $5.8B
  • What do Analysts Say About BUDZ or CAH?

    Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Cardinal Health has an analysts' consensus of $156.74 which suggests that it could grow by 1.49%. Given that Cardinal Health has higher upside potential than Weed, analysts believe Cardinal Health is more attractive than Weed.

    Company Buy Ratings Hold Ratings Sell Ratings
    BUDZ
    Weed
    0 0 0
    CAH
    Cardinal Health
    9 5 0
  • Is BUDZ or CAH More Risky?

    Weed has a beta of 0.835, which suggesting that the stock is 16.517% less volatile than S&P 500. In comparison Cardinal Health has a beta of 0.662, suggesting its less volatile than the S&P 500 by 33.768%.

  • Which is a Better Dividend Stock BUDZ or CAH?

    Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cardinal Health offers a yield of 1.31% to investors and pays a quarterly dividend of $0.51 per share. Weed pays -- of its earnings as a dividend. Cardinal Health pays out 58.57% of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BUDZ or CAH?

    Weed quarterly revenues are --, which are smaller than Cardinal Health quarterly revenues of $54.9B. Weed's net income of -$440.5K is lower than Cardinal Health's net income of $506M. Notably, Weed's price-to-earnings ratio is 180.00x while Cardinal Health's PE ratio is 24.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 0.17x for Cardinal Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BUDZ
    Weed
    -- 180.00x -- -$440.5K
    CAH
    Cardinal Health
    0.17x 24.09x $54.9B $506M
  • Which has Higher Returns BUDZ or COR?

    Cencora has a net margin of -- compared to Weed's net margin of 0.95%. Weed's return on equity of -- beat Cencora's return on equity of 183.42%.

    Company Gross Margin Earnings Per Share Invested Capital
    BUDZ
    Weed
    -- -$0.00 --
    COR
    Cencora
    4.06% $3.68 $9B
  • What do Analysts Say About BUDZ or COR?

    Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Cencora has an analysts' consensus of $317.23 which suggests that it could grow by 8.92%. Given that Cencora has higher upside potential than Weed, analysts believe Cencora is more attractive than Weed.

    Company Buy Ratings Hold Ratings Sell Ratings
    BUDZ
    Weed
    0 0 0
    COR
    Cencora
    9 6 0
  • Is BUDZ or COR More Risky?

    Weed has a beta of 0.835, which suggesting that the stock is 16.517% less volatile than S&P 500. In comparison Cencora has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.596%.

  • Which is a Better Dividend Stock BUDZ or COR?

    Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cencora offers a yield of 0.74% to investors and pays a quarterly dividend of $0.55 per share. Weed pays -- of its earnings as a dividend. Cencora pays out 27.58% of its earnings as a dividend. Cencora's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BUDZ or COR?

    Weed quarterly revenues are --, which are smaller than Cencora quarterly revenues of $75.5B. Weed's net income of -$440.5K is lower than Cencora's net income of $717.9M. Notably, Weed's price-to-earnings ratio is 180.00x while Cencora's PE ratio is 33.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 0.19x for Cencora. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BUDZ
    Weed
    -- 180.00x -- -$440.5K
    COR
    Cencora
    0.19x 33.79x $75.5B $717.9M
  • Which has Higher Returns BUDZ or LAB?

    Standard BioTools has a net margin of -- compared to Weed's net margin of -63.81%. Weed's return on equity of -- beat Standard BioTools's return on equity of -26.52%.

    Company Gross Margin Earnings Per Share Invested Capital
    BUDZ
    Weed
    -- -$0.00 --
    LAB
    Standard BioTools
    48.39% -$0.07 $454.9M
  • What do Analysts Say About BUDZ or LAB?

    Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 135.15%. Given that Standard BioTools has higher upside potential than Weed, analysts believe Standard BioTools is more attractive than Weed.

    Company Buy Ratings Hold Ratings Sell Ratings
    BUDZ
    Weed
    0 0 0
    LAB
    Standard BioTools
    2 1 0
  • Is BUDZ or LAB More Risky?

    Weed has a beta of 0.835, which suggesting that the stock is 16.517% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.804, suggesting its more volatile than the S&P 500 by 80.443%.

  • Which is a Better Dividend Stock BUDZ or LAB?

    Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Weed pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BUDZ or LAB?

    Weed quarterly revenues are --, which are smaller than Standard BioTools quarterly revenues of $40.8M. Weed's net income of -$440.5K is higher than Standard BioTools's net income of -$26M. Notably, Weed's price-to-earnings ratio is 180.00x while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 2.23x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BUDZ
    Weed
    -- 180.00x -- -$440.5K
    LAB
    Standard BioTools
    2.23x -- $40.8M -$26M
  • Which has Higher Returns BUDZ or MCK?

    McKesson has a net margin of -- compared to Weed's net margin of 1.39%. Weed's return on equity of -- beat McKesson's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BUDZ
    Weed
    -- -$0.00 --
    MCK
    McKesson
    4.01% $10.01 $4B
  • What do Analysts Say About BUDZ or MCK?

    Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand McKesson has an analysts' consensus of $748.84 which suggests that it could grow by 4.08%. Given that McKesson has higher upside potential than Weed, analysts believe McKesson is more attractive than Weed.

    Company Buy Ratings Hold Ratings Sell Ratings
    BUDZ
    Weed
    0 0 0
    MCK
    McKesson
    10 3 0
  • Is BUDZ or MCK More Risky?

    Weed has a beta of 0.835, which suggesting that the stock is 16.517% less volatile than S&P 500. In comparison McKesson has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.469%.

  • Which is a Better Dividend Stock BUDZ or MCK?

    Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. McKesson offers a yield of 0.38% to investors and pays a quarterly dividend of $0.71 per share. Weed pays -- of its earnings as a dividend. McKesson pays out 10.47% of its earnings as a dividend. McKesson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BUDZ or MCK?

    Weed quarterly revenues are --, which are smaller than McKesson quarterly revenues of $90.8B. Weed's net income of -$440.5K is lower than McKesson's net income of $1.3B. Notably, Weed's price-to-earnings ratio is 180.00x while McKesson's PE ratio is 27.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 0.26x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BUDZ
    Weed
    -- 180.00x -- -$440.5K
    MCK
    McKesson
    0.26x 27.86x $90.8B $1.3B
  • Which has Higher Returns BUDZ or PNPL?

    Pineapple has a net margin of -- compared to Weed's net margin of --. Weed's return on equity of -- beat Pineapple's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BUDZ
    Weed
    -- -$0.00 --
    PNPL
    Pineapple
    -- -- --
  • What do Analysts Say About BUDZ or PNPL?

    Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Pineapple has an analysts' consensus of -- which suggests that it could fall by --. Given that Weed has higher upside potential than Pineapple, analysts believe Weed is more attractive than Pineapple.

    Company Buy Ratings Hold Ratings Sell Ratings
    BUDZ
    Weed
    0 0 0
    PNPL
    Pineapple
    0 0 0
  • Is BUDZ or PNPL More Risky?

    Weed has a beta of 0.835, which suggesting that the stock is 16.517% less volatile than S&P 500. In comparison Pineapple has a beta of 36.643, suggesting its more volatile than the S&P 500 by 3564.318%.

  • Which is a Better Dividend Stock BUDZ or PNPL?

    Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pineapple offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Weed pays -- of its earnings as a dividend. Pineapple pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BUDZ or PNPL?

    Weed quarterly revenues are --, which are smaller than Pineapple quarterly revenues of --. Weed's net income of -$440.5K is higher than Pineapple's net income of --. Notably, Weed's price-to-earnings ratio is 180.00x while Pineapple's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 49.15x for Pineapple. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BUDZ
    Weed
    -- 180.00x -- -$440.5K
    PNPL
    Pineapple
    49.15x -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Salesforce Stock Be in 5 Years?
Where Will Salesforce Stock Be in 5 Years?

Salesforce (NYSE: CRM) just turned in a quarter that, on…

2 Ultra Safe Dividend Stocks to Buy Now
2 Ultra Safe Dividend Stocks to Buy Now

Historically, blue-chip dividend stocks have been good choices for periods…

Where Will Asana Stock Be in 5 Years?
Where Will Asana Stock Be in 5 Years?

Asana stock hasn’t given many investors on Wall Street any…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
31
REGN alert for May 31

Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.

Buy
55
RGC alert for May 31

Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.

Sell
42
AMBA alert for May 31

Ambarella [AMBA] is down 15.13% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock